Skip to main content
Premium Trial:

Request an Annual Quote

FDA Issues Emergency Use Authorization for UCLA NGS-Based SARS-CoV-2 Test

NEW YORK – The US Food and Drug Administration on Tuesday issued Emergency Use Authorization to UCLA's SwabSeq COVID-19 Diagnostic Platform for detecting SARS-CoV-2.

The device is for the qualitative detection of the coronavirus in nasopharyngeal swabs, oropharyngeal swabs, mid-turbinate nasal swabs, and anterior nasal swabs from individuals who are suspected of having COVID-19, the disease caused by SARS-CoV-2.

According to the FDA's authorization letter, the UCLA SwabSeq COVID-19 Diagnostic Platform is a next-generation sequencing-based in vitro diagnostic test and is intended for use by lab personnel trained to use Illumina's MiSeq and NextSeq systems. RNA extraction is performed using Thermo Fisher Scientific's Kingfisher instrument and the company's MagMax Viral/Pathogen Nucleic Acid Isolation kit. Reverse transcription and targeted PCR amplification is performed using Thermo Fisher's TaqPath 1-step RT-qPCR Master Mix with the Veriti 384-well thermal cycler. 

Testing with the platform can be done only at the UCLA Clinical Microbiology Laboratory.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.